Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fondaparinux for VTE Prophylaxis in Gynecologic Oncology Surgery
NCT00381888Phase 2Completed
- Sponsor
- Masonic Cancer Center
- Start
- Jan 2007
- Primary completion
- Jan 2009
- Modality
- Allosteric Modulators
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of fondaparinux in thromboembolism, sponsored by Masonic Cancer Center. Primary endpoint: Number of Patients With Venous Thromboembolism at 4 weeks. Started Jan 2007; status: completed.
02
Drugs
fondaparinux
03
Conditions
thromboembolism
Beyond the preview
Go deeper on NCT00381888.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00381888.